OMER: Omeros Prices $75 Million Public Offering of Common Stock and Pre-Funded Warrants


Omeros Corporation (NASDAQ:OMER) today announced that it has priced an underwritten public offering of 2,995,506 shares of its common stock at a per share price to the public equal to $20.03, and pre-funded warrants to purchase up to 749,250 shares of its common stock, at a per warrant price to the public equal to $20.02. The pre-funded warrants have a term of seven years and an exercise price of $0.01 per share. Total gross proceeds, including the approximately $15 million to be received on the pre-funded warrants, will be approximately $75 million. The net proceeds from this offering, after deducting the underwriters’ discounts and other estimated of… Read more ยป

Shares of Omeros closed yesterday at $20.03 . OMER has a 1-year high of $25.84 and a 1-year low of $9.76. The stock’s 50-day moving average is $23.02 and it’s 200-day moving average is $17.05.

On the ratings front, Omeros (NASDAQ:OMER) has been the subject of a number of recent research reports. In a report issued on November 20, Wedbush analyst Liana Moussatos reiterated a Buy rating on OMER, with a price target of $52, which reflects a potential upside of 159.6% from last closing price. Separately, on November 13, Maxim Group’s Jason Kolbert reiterated a Buy rating on the stock and has a price target of $28.

In total, 4 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $20.03 which is 14.8% above where the stock closed yesterday.

Omeros Corp is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts